AlzeCure Pharma
4.11.2021 10:21:53 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 04, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company is participating at Redeye Life Science Day 2021 on November 11 at 14:30 CEST, where CEO Martin Jönsson will present the company's latest developments. The presentation will be followed by a Q&A with external experts on-site and Redeye's analysts.
The presentation will be held in English and live streamed via https://www.redeye.se/events/815899/redeye-life-science-day-2021 . The recorded presentation and the slide set will also be available afterwards on AlzeCure's website https://www.alzecurepharma.se/en/presentations-and-interviews/ .
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.
FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure presents at Redeye Life Science Day 2021 on November 11
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/671149/AlzeCure-Presents-at-Redeye-Life-Science-Day-2021-on-November-11
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Fermi Announces Second Quarter 2026 Earnings Release and Call Date20.7.2026 22:30:00 CEST | Press release
Fermi to host earnings call on August 13, 2026 DALLAS, TX / ACCESS Newswire / July 20, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that it plans to release second quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, August 13, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 587288. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for
GA-ASI and KONGSBERG Advance JSM Integration for MQ-9B20.7.2026 12:05:00 CEST | Press release
Companies Bring Joint Strike Missile Weapon System to Leading Uncrewed Platform SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and KONGSBERG Gruppen ASA (KONGSBERG) completed the System Requirements Review (SRR) and Preliminary Design Review (PDR) for the integration of the Joint Strike Missile (JSM) weapon system onto MQ-9B. This design and integration effort is a jointly funded project by both companies aimed at providing long-range strike capability for MQ-9B and its customers. These reviews were successfully completed in Kongsberg, Norway, on June 30. MQ-9B is an industry-leading uncrewed aircraft system (UAS) manufactured by GA-ASI and includes the SkyGuardian® and SeaGuardian® models. KONGSBERG produces the JSM, a best-in-class weapon system for use against high-priority targets. "We recognize the value JSM brings to our MQ-9B platform," said Niki Johnson, GA-ASI Vice President, International Capture and Government Affairs. "
GA-ASI Completes Qualification Testing for UK Protector Weapons20.7.2026 12:00:00 CEST | Press release
Concludes 6-Year U.S. and U.K. Governmental and Industry Collaboration SAN DIEGO, CA / ACCESS Newswire / July 20, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has completed weapons testing for the Royal Air Force's (RAF) Protector RG Mk1 Remotely Piloted Aircraft, qualifying both the Paveway IV laser-guided bomb and the Brimstone 3 air-to-surface missile for launch from GA-ASI's MQ-9B aircraft. Testing was completed on June 18 at GA-ASI's facilities in Southern California and marked the first time that GA-ASI has taken the lead role in completing weapons qualification for a customer. The qualification testing was conducted under UK Ministry of Defence approval and met all requirements for certification of the safe carriage and release of weapons. "The Royal Air Force is our MQ-9B launch customer and we're here to support them in any way we can," said GA-ASI President David R. Alexander. "Leading the qualification test was a unique experience and we're excited to complete
ePropelled to Showcase Next Generation Electric Propulsion, Software Innovation and Autonomous Systems Capabilities at Farnborough International Airshow 202617.7.2026 17:00:00 CEST | Press release
Meet the ePropelled team in Hall 2, Stand 2039, on the New Hampshire Mission Pavilion FARNBOROUGH, UK / ACCESS Newswire / July 17, 2026 / ePropelled, a leading global provider of smart propulsion solutions and energy management systems, will exhibit at the Farnborough International Airshow 2026, showcasing its latest innovations for aerospace, defense and uncrewed vehicle applications. Visitors to Hall 2, Stand 2039 on the New Hampshire Mission Pavilion will have the opportunity to meet the ePropelled team and learn about a range of exciting developments, including new product launches, software innovations, technology updates and exclusive previews of next-generation solutions currently in development. With autonomy, electrification and intelligent mobility driving the future of aerospace and defence, ePropelled continues to develop advanced propulsion, power management and software technologies that enhance performance, efficiency and mission capability across air, land and maritime
As the UK Backs Life Sciences and Advanced Manufacturing, US PMO Firm MustardSeed Moves In to Help Deliver It16.7.2026 11:00:00 CEST | Press release
The expansion reflects growing client demand for embedded programme management support across highly regulated industries. WEST CHESTER, PA AND MANCHESTER, UK / ACCESS Newswire / July 16, 2026 / The UK Government's 2025 Modern Industrial Strategy has put life sciences, advanced manufacturing, defence, and clean energy at the centre of Britain's growth agenda. MustardSeed, a US-based programme management and PMO consultancy, is launching UK operations to help organisations in those sectors deliver on that ambition. The 2025 Modern Industrial Strategy names life sciences and advanced manufacturing among its eight priority sectors, alongside defence and clean energy. These are industries defined by complex, regulated, multi-stakeholder programmes where disciplined execution directly determines commercial and operational outcomes. MustardSeed, headquartered in West Chester, Pennsylvania, has built its practice around delivering that execution. The firm announced today the launch of its UK
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom